About SYNERGY THERAPEUTICS, INC
Synergy Therapeutics is a biotechnology company focused on developing SYN-126, a drug that restores p53 functions to combat various cancers. The company is a spin-out from the Philadelphia College of Pharmacy and has licensed exclusive rights to multiple patents.
Development of SYN-126, a tumoricidal drug that targets p53 inhibitors and antiapoptotic proteinsLicensing of human serum albumin (HSA) platform technology for peptide-drug conjugates (PDCs)Conducting preclinical studies including pharmacokinetics and ADMEPlanning for IND-enabling studies and Phase 1/2 clinical trials
Is this your company?
Claim SYNERGY THERAPEUTICS, INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim SYNERGY THERAPEUTICS, INC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.